ClinicalTrials.gg
Active, not recruitingNCT03869892SOLSTICEUpdated Nov 13, 2026

Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.

A Phase 3 interventional study of Trifluridine/tipiracil hydrochloride (S95005) and Capecitabine in Metastatic Colorectal Cancer, sponsored by Institut de Recherches Internationales Servier. Active, not recruiting at 190 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Institut de Recherches Internationales Servier · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
856
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies in Colorectal Neoplasms with a site in Russia — 4 open to participants now, 13 under way, 2 of them phase 3. Colorectal Neoplasms · Russia.

Enrollment
2nd of 20
856 · median 244
Started
2019
with 2 others
Phase 3
5 of 22
none open now
Primary completion
2021-06
later than 0 of 12 live
Registered
4th of 22
by date
Lead sponsor
1 of 22
Institut de Recherches Internationales Servier

Among the 22 studies in Colorectal Neoplasms with a site in Russia, this one is the 2nd largest by enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2019, is one of 5 in phase 3, reaches primary completion later than 0 of the 12 other live ones, and was the 4th registered.

Colorectal Neoplasms

6,555 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

4 of the 22 studies in Colorectal Neoplasms with a site in Russia are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Colorectal Neoplasms with a site in Russia, or all of them as a file.
02

Study summary

The main purpose of this study is to demonstrate the superiority of S 95005 in combination with bevacizumab over capecitabine in combination with bevacizumab.

03

Conditions studied

  • Metastatic Colorectal Cancer

Keywords

  • Metastatic
  • Cancer
  • Colorectal
  • Colorectal Cancer
  • Colon
  • Rectum
  • Metastasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has definitive confirmed adenocarcinoma of the colon or rectum (all other histological types are excluded). Primary tumour localisation must be known.
  2. RAS status based on local biological assessment of tumour must be available. If RAS status is not available at the time of randomisation, tumour biopsy must be available for RAS status determination (based on local biological assessment).
  3. Patient is not a candidate for standard full dose combination chemotherapy with irinotecan or oxaliplatin
  4. Patient is not a candidate for curative resection of lesions.
  5. No previous systemic anticancer therapy for unresectable metastatic colorectal cancer.
  6. (Eastern Cooperative Oncology Group) performance status ≤2.
  7. Adequate organ function (renal, haematological, hepatic, coagulation) as described in the study protocol'

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy, breastfeeding or possibility of becoming pregnant during the study.
  2. Participation in another interventional study within 4 weeks prior to the randomisation .
  3. Patients who have not recovered from non-hematologic grade ≥ 3 toxicity of previous anticancer therapy prior to the randomisation.
  4. Symptomatic central nervous system .
  5. Major surgery within 4 weeks prior to the randomisation.

    Exclusion criteria related to S 95005 administration:

  6. History of allergic reactions attributed to compounds of similar composition to S 95005 or any of its .
  7. Any present in the SmPC of trifluridine/tipiracil

    Exclusion criteria related to bevacizumab administration:

  8. Any contraindication present in the SmPC of bevacizumab

    Exclusion criteria related to capecitabine administration:

  9. Any contraindication present in the SmPC of capecitabine
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
856 participants (actual)

Study arms

  • Experimental
    S95005 + Bevacizumab

    Drug: Trifluridine/tipiracil hydrochloride (S95005) · Biological: Bevacizumab experimental

  • Active comparator
    Capecitabine + Bevacizumab

    Drug: Capecitabine · Biological: Bevacizumab control

Interventions

  • DrugTrifluridine/tipiracil hydrochloride (S95005)

    Film-coated tablets of S 95005 (35 mg/m²/dose) will be administered orally twice a day (BID), within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 2 weeks, followed by a 14-day rest; This treatment cycle will be repeated every 4 weeks.

  • Film-coated tablets, Capecitabine (1250 mg/m²/dose) will be administered orally BID on Days 1-14 of each cycle. This treatment cycle will be repeated every 3 weeks.

  • BiologicalBevacizumab experimental

    Concentrate for solution for infusion, Bevacizumab (5 mg/kg, IV) administered every 2 weeks (Day 1 and Day 15). This treatment cycle will be repeated every 4 weeks.

  • BiologicalBevacizumab control

    Concentrate for solution for infusion, Bevacizumab (7.5 mg/kg, IV) will be administered on Day 1 of each cycle.This treatment cycle will be repeated every 3 weeks.

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    Time elapsed between the randomization and the date of radiological tumour progression (according to RECIST 1.1) or death from any cause.

    Time frame: Up to 24 months

Secondary outcomes

  1. Overall Survival (OS)

    Time elapsed between the date of randomization and the date of death due to any cause.

    Time frame: Up to 8 years

  2. Overall response rate (ORR)

    The proportion of patients with objective evidence of complete response (CR) or partial response (PR) according to RECIST 1.1 criteria and using investigator's tumour assessment.

    Time frame: Up to 8 years

  3. Disease control rate (DCR)

    The proportion of patients with objective evidence of CR or PR or stable disease (SD) according to RECIST 1.1 criteria and using investigator's tumour assessment.

    Time frame: Up to 8 years

  4. Duration of response (DoR)

    The time from the first documentation of response (CR or PR) to the first documentation of objective tumour progression or death due to any cause, whichever occurs first.

    Time frame: Up to 8 years

  5. Time to treatment failure (TTF)

    The time from randomization to treatment discontinuation for any reason, including disease progression, treatment toxicity, patient preference, or death.

    Time frame: Up to 8 years

  6. Incidence of Adverse Events (AEs)

    Time frame: Up to 8 years

  7. Number of clinically significant changes to hematology, biochemistry, coagulation and urinalysis tests

    Time frame: Up to 8 years

  8. Changes in ECOG performance status

    Time frame: Up to 8 years

  9. Number of clinically significant changes to blood pressure, heart rate, body temperature and body weight

    Time frame: Up to 8 years

  10. Number of clinically significant changes to 12-leads ECG parameters

    Time frame: Up to 8 years

  11. Quality of life as assessed by EORTC QLQ-C30

    European organization for research and treatment of cancer (EORTC) Quality of Life Questionnaire - Core Questionnaire (QLQ-C30) scores range from 0-100 and assess functional and symptom scores. For functional scores, a higher score represents an increase in functioning. For symptom scores, a higher score represents an increase in symptoms.

    Time frame: Up to 8 years

  12. Quality of life as assessed by EQ-5D-5L

    The 5-level EQ-5D version questionnaire scores range from 5 to 25 with a higher score representing a worse health status.

    Time frame: Up to 8 years

07

Study locations

190 sites
  • Centro de Oncología e Investigación de Buenos Aires COIBA
    Berazategui, B1884BBF, Argentina
  • Hospital de Gastroenterología Dr. Carlos Borino Udaondo Oncology Unit
    Buenos Aires, 1264, Argentina
  • Fundación Favaloro Oncology Unit
    Buenos Aires, C1093AAS, Argentina
  • Instituto Alexander Fleming
    Buenos Aires, C1426ANZ, Argentina
  • Hospital Universitario CEMIC Servicio de Oncología, Unidad de tumores gastrointestinales
    Buenos Aires, C1431FWO, Argentina
  • Centro Oncológico Riojano Integral CORI Fundación CORI para la Investigación y Prevención del Cáncer
    La Rioja, F5300COE, Argentina
  • Fundación COIR Centro Oncológico de Interación Regional
    Mendoza, 5500, Argentina
  • Centro Médico San Roque
    San Miguel de Tucumán, T4000IAK, Argentina
  • Instituto de Oncología de Rosario
    Santa Fe, S2000KZE, Argentina
  • ISIS Centro especializado
    Santa Fe, S3000FFU, Argentina
  • Blacktown Hospital Cancer and Haematology Centre
    Blacktown, 2148, Australia
  • Frankston Private Peninsula and Southeast Oncology Group
    Frankston, 3199, Australia
  • Lake Macquarie Private Hospital
    Gateshead, 2290, Australia
  • St George Hospital St George Hospital Cancer Care Centre
    Kogarah, 2217, Australia
  • Adventist HealthCare Integrated Cancer Centre
    Wahroonga, 2076, Australia
  • Southern Medical Day Care Centre
    Wollongong, 2500, Australia
  • Med. Universität Graz Klinische Abteilung für Onkologie
    Graz, 8036, Austria
  • Medizinische Universität Innsbruck Univ.-Klinik für Innere Medizin V
    Innsbruck, 6020, Austria
  • Ordensklinikum Linz Barmherzige Schwestern Interne I
    Linz, 4010, Austria
  • Landeskrankenhaus (SALK) Universitätsklinik für Innere Medizin III (SALK)
    Salzburg, 5020, Austria
  • Universitätsklinikum St. Pölten Klinische Abteilung für Innere Medizin I
    Sankt Pölten, 3100, Austria
  • Allgemeines Krankenhaus - Universitätskliniken Klinische Abteilung für Onkologie
    Vienna, 1090, Austria
  • Hospital do Câncer de Barretos - Fundação Pio XII Unidade de Pesquisa Clínica
    Barretos, 14784-400, Brazil
  • Cenantron - Clinica
    Belo Horizonte, 30150-320, Brazil
  • Sirio Libanes DF - Centro de Oncologia de Braslia do Sirio- Centro Intergrado de Pesquisa
    Brasília, 70200-730, Brazil
  • Centro de Pesquisa Hospital de Caridade de Ijuí Unidade de Pesquisa Clínica
    Ijuí, 98700-000, Brazil
  • Hospital Mae de Deus Oncologia
    Porto Alegre, 90880-480, Brazil
  • Hospital São Rafael Centro Intergrado de Pesquisa
    Salvador, 41253-191, Brazil
  • CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncol Centro Intergrado de Pesquisa
    Santo André, 09060-870, Brazil
  • Hospital de Base Centro Integrado de Pesquisa
    São José do Rio Preto, 15090-000, Brazil
  • ICESP - Instituto do Câncer do Estado de São Paulo Centro Integrado de Pesquisa
    São Paulo, 01246-000, Brazil
  • Hospital A C Camargo Unidade de Pesquisa Clinica
    São Paulo, 01509-900, Brazil
  • "Complex oncology center - Burgas" EOOD Department of medical oncology
    Burgas, 8000, Bulgaria
  • "Multiprofile hosp. for active treatmen Dr. Tota Venkova" AD Department of medical oncology
    Gabrovo, 5300, Bulgaria
  • "Complex oncology center - Plovdiv" EOOD, IInd base Dpt. of Med. oncology and onc. diseases in gastroenterology
    Plovdiv, 4004, Bulgaria
  • "Medical Center Nadezhda Clinical" EOOD Medical Oncology Department
    Sofia, 1330, Bulgaria
  • "UMHAT Sv. Ivan Rilski" EAD Clinic of clinical hematology, Dpt. of medical oncology
    Sofia, 1431, Bulgaria
  • MHAT Serdika EOOD Department of Medical Oncology
    Sofia, 1632, Bulgaria
  • Spec. hospital for active treatment of oncology dis. EOOD Department of medical oncology and palliative care
    Sofia, 1756, Bulgaria
  • SHAT of oncology diseases Dr. Marko Antonov Markov" EOOD Department of medical oncology and palliative therapy
    Varna, 9003, Bulgaria
  • "Complex Ongology Center - Vratsa" EOOD Department of Medical oncology
    Vratsa, 3000, Bulgaria
  • Masarykuv onkologicky ustav Klinika komplexni onkologicke pece
    Brno, 656 53, Czechia
  • Fakultni nemocnice Ostrava Klinika onkologicka
    Ostrava, Czechia
  • Vseobecna fakultni nemocnice Onkologicka klinika VFN a 1. LF UK
    Prague, 128 08, Czechia
  • Thomayerova nemocnice Onkologicka klinika 1. LF UK a TN
    Prague, 140 59, Czechia
  • Fakultni nemocnice Olomouc Onkologicka klinika
    Prague, 77900, Czechia
  • Aalborg Universitetshospital, Syd Onkologisk Afdelin
    Aalborg, 9000, Denmark
  • Rigshospitalet Onkologisk Klinik
    Copenhagen, 2100, Denmark
  • Regionshospitalet Herning, Hospitalsenheden Vest Onkologisk Afdeling
    Herning, 7400, Denmark
  • Odense Universitetshospital Onkologisk Afdeling R
    Odense, 5000, Denmark
  • East Tallinn Central Hospital Center of Oncology
    Tallinn, 11312, Estonia
  • North Estonia Medical Centre Foundation Oncology and Haematology clinic
    Tallinn, 13419, Estonia
  • Tartu University Hospital, Hematology - Oncology clinic, Radiotherapy and oncological therapy
    Tartu, 51014, Estonia
  • Institut Sainte Catherine
    Avignon, 84918, France
  • CHU Jean Minjoz Service d'oncologie médicale
    Besançon, 25030, France
  • CHU Morvan Institut de Cancérologie et d'Hématologie
    Brest, 29200, France
  • Hopital Privé Jean Mermoz Service de Gastro entérologie et d'Oncologie médicale
    Lyon, 69008, France
  • Hôpital Nord Franche-Comté - Site du Mittan Service d'oncologie médicale
    Montbéliard, 25209, France
  • Centre Antoine Lacassagne Dpt d'Oncologie Médicale
    Nice, 06189, France
  • Hôpital Saint-Antoine Service d'Oncologie Médicale
    Paris, 75012, France
  • Hôpital Européen Georges Pompidou Oncologie Hépatogastroenterologie-oncologie digestive
    Paris, 75015, France
  • Hopital Haut-Leveque Hepato-gastroenterologie et oncologie digestive
    Pessac, 33604, France
  • CHU Toulouse Rangueil Oncologie médicale digestive
    Toulouse, 31059, France
  • Onkologische Schwerpunktpraxis Kurfuerstendamm
    Berlin, 10707, Germany
  • Lübecker Onkologische Schwerpunktpraxis im Hochschulstadttei
    Lübeck, 23562, Germany
  • Klinikum der Universität München Campus Großhadern, Medizinische Klinik und Poliklinik III
    München, 81377, Germany
  • Magyar Honvedseg Egeszsegugyi Kozpont Onkologiai Osztaly
    Budapest, 1062, Hungary
  • Semmelweis University Radiology and Oncotherapy Clinic
    Budapest, 1083, Hungary
  • Del-Pesti Centrumkh-Orsz. Hematologiai es Infektologiai Int. Szent Laszlo Telephely
    Budapest, 1097, Hungary
  • Szent Imre Egyetem Oktatokorhaz Klinikai Onkologia
    Budapest, 1115, Hungary
  • Orszagos Onkologiai Intezet "B" Belgyogyaszati-Onkologiai O. Es Klin. Farmakologiai O.
    Budapest, 1122, Hungary
  • Uzsoki Utcai Korhaz Onkoradiologiai Osztaly
    Budapest, 1145, Hungary
  • Debreceni Egyetem Orvos es Egeszsegtudomanyi Centrum Onkologiai Intezet
    Debrecen, 4032, Hungary
  • Petz Aladar Megyei Oktato Korhaz Onkoradiologiai Osztaly
    Győr, 9024, Hungary
  • Bekes Megyei Kozponti Korhaz
    Gyula, 57000, Hungary
  • Bacs-Kiskun Megyei Korhaz Onkoradiologiai Kozpont
    Kecskemét, 6000, Hungary
  • Szabolcs-Szatmar-Bereg Megyei Korhazak Onkoradiologiai Osztaly
    Nyíregyháza, 4400, Hungary
  • Pecsi Tudomanyegyetem, Klinikai Kozpont Onkoterapias Intezet
    Pécs, 7624, Hungary
  • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kp. Onkoterápiás Klinika
    Szeged, 6720, Hungary
  • JNSZ Megyei Hetenyi Geza Korhaz es Rendelointezet Megyei Onkologiai Centrum
    Szolnok, 5004, Hungary
  • Markusovsky Egyetemi Oktatokorhaz Onkoradiologiai Osztaly
    Szombathely, 9700, Hungary
  • Zala Megyei Korhaz Onkologiai osztaly
    Zalaegerszeg, 8900, Hungary
  • Bon Secours Hospital
    Cork, 90, Ireland
  • Cork University Hospital Department of Medical Oncology
    Cork, T12 DC4A, Ireland
  • The Adelaide and Meath Hospital
    Dublin, D24 NROA, Ireland
  • Azienda Policlinico Universitaria - Presidio Monserrato Oncologia Medica
    Cagliari, 09100, Italy
  • Azienda Socio Sanitaria Territoriale di Cremona ONCOLOGIA
    Cremona, 26100, Italy
  • Istituto Nazionale Tumori I.R.C.C.S "Fondazione G. Pascale" Struttura Complessa di Oncologia Medica Addominale
    Naples, 80131, Italy
  • Istituto Oncologico Veneto IOV - IRCCS Unità Operativa Complessa Oncologia Medica 1
    Padova, 35128, Italy
  • A.O.U. Pisana-Ospedale Santa Chiara U.O. di Oncologia Medica 2
    Pisa, 56126, Italy
  • Ospedale San Carlo U.O. Oncologia Medica
    Potenza, 85100, Italy
  • Arcispedale Santa Maria Nuova Unità di Oncologia
    Reggio Emilia, 42123, Italy
  • Policlinico Universitario Campus Biomedico UOC di Oncologia Medica
    Roma, 00128, Italy
  • Istituto Clinico Humanitas I.R.C.C.S Dipartimento di Oncologia Medica ed Ematologia
    Rozzano (MI), 20089, Italy
  • IRCSS Casa Sollievo della Sofferenza Dipartimento Onco-Ematologia
    San Giovanni Rotondo, 71013, Italy
  • Ospedale S. Bortolo -ULSS8 Berica Distretto Est U.O. ONCOLOGIA
    Vicenza, 36100, Italy
  • P. Stradins Clinical University Hospital
    Riga, 1002, Latvia
  • Riga East Univerity Hospital Oncology Centre of Latvia
    Riga, 1079, Latvia
  • Oncology Hospital, Branch of Hospital of Lithuanian Uni. of Health Sciences Kauno klinikos
    Kaunas, 45434, Lithuania
  • Hospital of Lithuania Univ of Health Sciences Kauno klinikos Oncology Institute
    Kaunas, LT-50161, Lithuania

Showing the first 100 of 190 sites across 25 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Andre T, Falcone A, Shparyk Y, Moiseenko F, Polo-Marques E, Csoszi T, Campos-Bragagnoli A, Liposits G, Chmielowska E, Aubel P, Martin L, Fougeray R, Amellal N, Saunders MP. Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study. Lancet Gastroenterol Hepatol. 2023 Feb;8(2):133-144. doi: 10.1016/S2468-1253(22)00334-X. Epub 2022 Dec 2. PubMed 36470291 ↗

Individual participant data

Plan to share: Yes — Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data. Access can be requested for all interventional clinical studies: used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US). where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope. In addition, access can be requested for all interventional clinical studies in patients: sponsored by Servier with a first patient enrolled as of 1 January 2004 onwards for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: After Marketing Authorisation in EEA or US if the study is used for the approval.

Access criteria: Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.

Data sharing details ↗ · clinicaltrials.servier.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Jun 2021, 27 months.

Of 106 non-industry phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 116. This study's 27 months is below that.

Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2018
First posted
Mar 11, 2019
StartActual
Mar 21, 2019
Primary completionActual
Jun 29, 2021
CompletionEst.
Dec 31, 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers and verification date
1 update, last Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Minor edits only
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03869892
Lead sponsor
Institut de Recherches Internationales Servier
Collaborators
ADIR, a Servier Group company
Responsible party
Sponsor
First posted
Mar 11, 2019
Start date
Mar 21, 2019
Primary completion
Jun 29, 2021
Completion
Dec 31, 2026 (estimated)
Last update
Nov 13, 2026

Study contacts

Thierry ANDRE, PhD
principal investigator · Medical Oncology departement Saint-Antoine hospital (Paris France 75012)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion